Abalone Bio

Abalone Bio is a biotechnology company in Emeryville, California, that discovers and designs antibody therapeutics with a platform combining high throughput functional screening and machine learning. Its Functional Antibody Selection Technology, known as FAST, uses engineered yeast cells to measure the functional activity of hundreds of millions of antibodies at once, rather than screening only for binding affinity. The activity data produced by these screens trains models that the company uses to design new antibodies, not just to filter existing ones. This is not a self serve software product. It is relevant to pharmaceutical and biotechnology partners looking for antibody candidates against targets that conventional discovery struggles with. Its stated focus is activating antibodies for G protein coupled receptors, which it describes as the hardest target class for antibodies because activation requires precise structural changes rather than simple dimerization. The intended clinical benefit is therapies with fewer side effects, and the company pursues both an internal pipeline, with undisclosed indications, and partnered programs. There is no pricing. Engagements are partnership or licensing arrangements negotiated directly with the company, which invites partnership inquiries through its site. The leadership team was drawn from antibody discovery, data science and drug development roles at companies including XOMA, Zymergen and Atomwise, and the platform's proprietary activity datasets and design models are the core asset rather than any single product.